DXL Board Rejects Zodiac Partners II Revised Tender — $4.25 Per Share Spurned

Destination XL Group's board told shareholders Monday to reject Zodiac Partners II's revised tender offer, the second rebuff in what has become a protracted fight for control of the $140 million market-cap Big + Tall menswear retailer. The revised offer sits at $4.25 per share, a figure the Canton, Massachusetts-based company's directors deemed inadequate after consultation with financial advisors. No counteroffer was floated.

Zodiac Partners II, a vehicle controlled by activist investor Harry Drnec, first approached DXL with an unsolicited tender in late May. That initial proposal drew immediate board resistance. The revised structure announced last week added modest consideration and technical adjustments to the tender mechanics, but left the fundamental valuation framework unchanged. DXL's statement on Monday reiterated that shareholders should not tender their shares, effectively freezing the activist's path to board representation absent a material price improvement or proxy contest.

The standoff matters because DXL operates in a category with structural moats — 350+ store footprint targeting a demographically stable cohort with limited omnichannel alternatives — but persistent margin pressure. The company posted $515 million in trailing revenue with a gross margin in the low-40s, constrained by inventory turn challenges and promotional cadence in an inflationary environment. Zodiac's thesis likely hinges on operational tightening and potential takeout optionality once control shifts, but the board's calculus appears anchored to near-term valuation compression that underprices the normalized EBITDA profile. The rejection also signals that DXL's directors either see a credible path to independent value creation or expect a higher bidder to emerge if Zodiac's stalking horse behavior flushes out strategic interest from private equity or consolidators in the specialty retail space.

For allocators, the setup now tilts toward three discrete scenarios. First, Zodiac escalates with a hostile proxy campaign ahead of the next annual meeting, likely in Q2 2027, forcing a board composition fight that could drag the stock into a $3.80–$4.50 trading band depending on retail sentiment and activist success probability. Second, a white knight surfaces — either a PE shop with omnichannel roll-up ambitions or a strategic like Torrid or Casual Male XL remnants — bidding north of $5.00 to preempt Zodiac and lock in the DXL customer file. Third, the bid dies and DXL executes independently, in which case the equity drifts back toward $3.20–$3.60 absent meaningful same-store sales improvement or margin inflection. The board's explicit recommendation to reject suggests confidence in scenario two or three, but the lack of a poison pill amendment or NOL preservation plan leaves the door ajar for scenario one if Zodiac decides the asset justifies a prolonged fight.

Watch for Zodiac's next move within 10 business days — either a raised offer, a formal proxy solicitation filing, or a withdrawal that signals the activist has moved on. DXL's Q2 earnings, expected late August, will clarify whether the board's valuation confidence rests on improving fundamentals or simply a belief that $4.25 underprices liquidation value in a distressed scenario.

The board's language was firm, but the absence of a simultaneous asset sale process or management buyout talk suggests DXL believes it can outlast Zodiac without offering shareholders a structured alternative. That confidence will be tested if same-store sales slip below the -2% threshold in the next two quarters.